Association between up‐titration of medical therapy and total hospitalizations and mortality in patients with recent worsening heart failure across the ejection fraction spectrum
Vasiliki Bistola(National and Kapodistrian University of Athens), Gerasimos Filippatos(National and Kapodistrian University of Athens), Faı̈ez Zannad(Inserm), Wouter Ouwerkerk(Université Bourgogne Franche-Comté), Effie Polyzogopoulou(National and Kapodistrian University of Athens), Marco Metra(GoHypersonic (United States)), Dimitrios Farmakis, Adriaan A. Voors, John Parissis(Onassis Cardiac Surgery Center), Kalliopi Keramida(National and Kapodistrian University of Athens), Nilesh J. Samani(University of Leicester), Stefan D. Anker, Panagiotis Simitsis(National and Kapodistrian University of Athens), Dirk J. van Veldhuisen(University Medical Center Groningen), John G.F. Cleland(Imperial College London)
Cited by 16
Related Papers
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
|European Heart Journal|2011|3.5k
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|Survey of Anesthesiology|2000|2.9k